RxDoctor Payments Data

Parinda Fruchtman, MD

Family Medicine · Salisbury, NCNPI 1831277425

Payments from drug & device makers

$16,369in general payments, 2019–2025

Across 905 payments — averaging $18.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AstraZeneca$1K
  • Astellas Pharma US Inc$1K
  • Collegium Pharmaceutical, Inc.$1K
  • Pfizer$759
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$15,75796%
  • Education$6114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)237$3,282
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC83$1,414
AstraZeneca44$1,293
Astellas Pharma US Inc42$1,166
Collegium Pharmaceutical, Inc.54$1,109
Pfizer46$759
Vanda Pharmaceuticals Inc.49$706
Forte Bio-pharma LLC17$698
Amgen38$645
Lilly USA, LLC31$516
Johnson & Johnson29$432
Novo Nordisk21$425
Scilex Pharmaceuticals Inc.20$405
GSK21$320
Paratek Pharmaceuticals, Inc.12$272
Mylan Specialty L.p.19$261
Boehringer Ingelheim10$172
Ironwood Pharmaceuticals, Inc9$166
Sanofi-aventis U.S. LLC7$139
Sunovion Pharmaceuticals Inc.7$127
Biohaven Pharmaceutical Holding Company Ltd.9$127
Takeda Pharmaceuticals U.S.A., Inc.6$118
Novartis6$108
Boston Scientific2$106
Eisai Inc.6$103
Exact Sciences1$101
Dexcom, Inc.5$98
Bayer5$87
Corcept Therapeutics4$75
Ardelyx, Inc.4$74
Daiichi Sankyo Inc.4$74
Supernus Pharmaceuticals, Inc.4$73
Verona Pharma, Inc.4$70
Biodelivery Sciences International, Inc.4$67
GRT US Holding, Inc.3$66
Virtus Pharmaceuticals LLC3$54
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)3$47
Idorsia Pharmaceuticals US Inc2$41
Teva Pharmaceuticals USA, Inc.3$41
Xeris Pharmaceuticals, Inc.2$37
Impel Pharmaceuticals Inc.2$36
Impel Pharmaceuticals LLC2$35
IBSA Pharma Inc.2$35
Biohaven Pharmaceuticals, Inc.2$31
Avanir Pharmaceuticals, Inc.2$30
Kowa Pharmaceuticals America, Inc.2$29
Amarin Pharma, Inc.2$27
Redhill Biopharma Inc.1$23
Avanos Medical1$23
Phathom Pharmaceuticals, Inc.1$21
Sumitomo Pharma America, Inc.1$21
Lundbeck LLC1$21
Valinor Pharma, LLC1$20
Abbott1$19
Merck1$18
Neurocrine Biosciences, Inc.1$17
Almatica Pharma LLC1$17
Tonix Medicines, Inc.1$16
Shield Therapeutics Inc1$16
Otsuka America Pharmaceutical, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,369 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$58,328
Medicare patients
91
Services billed
706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ArexvyRsvpref3 Antigen/As01e/Pf256$76,588
LinzessLinaclotide95$63,121
JardianceEmpagliflozin53$62,846
Xtampza ErOxycodone Myristate118$59,077
ShingrixVaricella-Zoster Ge/As01b/Pf237$50,590
UbrelvyUbrogepant34$46,142
OzempicSemaglutide49$45,809
EliquisApixaban47$45,620
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen803$27,216
MyrbetriqMirabegron44$26,989
JanuviaSitagliptin Phosphate27$24,058
Nucynta ErTapentadol Hcl17$23,038
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,443
MounjaroTirzepatide19$19,380
VraylarCariprazine Hcl14$19,104

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKArexvy, Shingrix, Trelegy Ellipta, Breo Ellipta$320$162,723541 claims
AbbVieLinzess, Ubrelvy, Vraylar, Qulipta$3,282$142,508154 claims
Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca$1,109$90,334149 claims
Boehringer IngelheimJardiance$172$62,84653 claims
Novo NordiskOzempic$425$45,80949 claims
PfizerEliquis$759$45,62047 claims
AstraZenecaSymbicort, Breztri Aerosphere, Farxiga$1,293$41,73599 claims
MerckJanuvia, Janumet$18$40,13045 claims
Astellas Pharma US IncMyrbetriq$1,166$26,98944 claims
Lilly USA, LLCMounjaro$516$19,38019 claims
Redhill Biopharma Inc.Movantik$23$9,88318 claims
BayerKerendia$87$8,21913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Salisbury

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →